An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI

International Journal of Biological Sciences

Volumn 5, Issue 7, 2009, Pages 637-646

  Song, Xuelei ^a   Fischer, Paul ^a   Chen, Xun ^a   Burton, Charlotte ^a   Wang, Jun ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Challenge MediTech Company Ltd   (China)

Author keywords

Apolipoprotein; D 4F; HDL; Mimetics; RCT; SR BI

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; CHOLESTEROL ESTER; D 4F PEPTIDE; D-4F PEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; NANOPARTICLE; PHOSPHOLIPID; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B;

ARTICLE; CELL LINE; FLUORESCENCE; GENE TRANSFER; GENETICS; HUMAN; IMMUNOLOGY; LIVER; LIVER CELL; METABOLISM; MOLECULAR MIMICRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; APOLIPOPROTEIN A-I; BLOTTING, WESTERN; CELL LINE; CHOLESTEROL; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENCE; GENE TRANSFER TECHNIQUES; HEPATOCYTES; HUMANS; LIVER; MOLECULAR MIMICRY; NANOPARTICLES; PHOSPHOLIPIDS; SCAVENGER RECEPTORS, CLASS B;

EID: 74049098646     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5.637     Document Type: Article

References (36)

1. Kwiterovich PO Jr.: State-of-the-art update and review: clinical trials of lipid-lowering agents. Am J Cardiol 1998; 82: 3U-17U.
2. deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51: 2199-211.
3. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-16.
4. Shieh SM, Shen MM, Tsai WJ, Shiuan LR, Wang DJ: Serum lipids and lipoprotein abnormalities in patients with thrombotic stroke--with exploring the protective role of HDL sub-fractions. Proc Natl Sci Counc Repub China B 1985; 9: 298-304.
5. Matsuda Y, Hirata K, Inoue N, Suematsu M, Kawashima S, Akita H, Yokoyama M: High density lipoprotein reverses in-hibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 1993; 72: 1103-9.
6. Hayek T, Oiknine J, Dankner G, Brook JG, Aviram M: HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995; 33: 721-5.
7. Navab M, Anantharamaiah GM, Fogelman AM: The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005; 15: 158-61.
8. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353: 265-7.
9. Paszty C, Maeda N, Verstuyft J, Rubin EM: Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903.
10. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, Nilsson J: Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholes-terolemic rabbits. Circulation 1994; 90: 1935-41.
11. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y, Natio M, et al.: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1882-8.
12. Chiesa G, Monteggia E, Marchesi M, Lorenzon P, Laucello M, Lorusso V, Di Mario C, Karvouni E, Newton RS, Bisgaier CL, Franceschini G, Sirtori CR: Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002; 90: 974-80.
13. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Jama 2003; 290: 2292-300.
14. Eisenberg S: High density lipoprotein metabolism. J Lipid Res 1984; 25: 1017-58.
15. Meng QH, Calabresi L, Fruchart JC, Marcel YL: Apolipoprotein A-I domains involved in the activation of lecithin: cholesterol acyltransferase. Importance of the central domain. J Biol Chem 1993; 268: 16966-73.
16. Acton SL, Scherer PE, Lodish HF, Krieger M: Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 1994; 269: 21003-9.
17. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ: Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003; 108: 661-3.
18. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25: 1325-31.
19. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM: Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 2006; 3: 540-7.
20. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM: Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001; 42: 1096-104.
21. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM: Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105: 290-2.
22. Chen X, Burton C, Song X, McNamara L, Langella A, Cianetti S, Chang CH, Wang J: An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration. Int J Biol Sci 2009; 5: 489-99.
23. Hirz R, Scanu AM: Reassembly in vitro of a serum high-density lipoprotein. Biochim Biophys Acta 1970; 207: 364-7.
24. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A: High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007; 81: 8063-71.
25. Pitas RE, Innerarity TL, Weinstein JN, Mahley RW: Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy. Arteriosclerosis 1981; 1: 177-85.
26. Liadaki KN, Liu T, Xu S, Ishida BY, Duchateaux PN, Krieger JP, Kane J, Krieger M, Zannis VI: Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem 2000; 275: 21262-71.
27. Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KAJr: Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 2005; 97: 1190-7.
28. Mineo C, Shaul PW: Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc Med 2007; 17: 156-61.
29. Feng Y, van Eck M, Van Craeyveld E, Jacobs F, Carlier V, Van Linthout S, Erdel M, Tjwa M, De Geest B: Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood 2009; 113: 755-64.
30. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, Hough G, Bachini E, Garber DW, Mishra VK, Palgunachari MN, Fogelman AM: An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1932-7.
31. Berens C, Hillen W: Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes. Eur J Biochem 2003; 270: 3109-21.
32. Liu T, Krieger M, Kan HY, Zannis VI: The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J Biol Chem 2002; 277: 21576-84.
33. Zannis VI, Chroni A, Krieger M: Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006; 84: 276-94.
34. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM: Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109: 3215-20.
35. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hama S, Reddy ST, Fogelman AM: Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 2007; 48: 2344-53.
36. Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-32.